Markets:

Overview

News

Currencies

International

Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.240 -2.990 (-70.69%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Chart Of The Day: Aldeyra - Skyrocketing ↗

April 11, 2023

Revenue is expected to grow by 2,045.80% next year. Earnings are estimated to increase by 16.90% next year and continue to compound at an annual rate of 73.70% for the next 5 years.

Via Talk Markets

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) Records 52-Week High Monday Morning

April 10, 2023

Via Investor Brand Network

Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis

April 06, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough

March 30, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Earnings Outlook For Aldeyra Therapeutics ↗

March 08, 2023

Via Benzinga

Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder ↗

October 06, 2022

Via Benzinga

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4 ↗

March 28, 2023

Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...

Via Benzinga

BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗

March 27, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

March 24, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday ↗

March 23, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa

March 16, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

March 09, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma

March 02, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights

March 01, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients ↗

February 28, 2023

Via Benzinga

Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease

February 28, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗

February 23, 2023

An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...

Via Benzinga

Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy

February 23, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials

February 16, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

February 09, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

February 07, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma

December 21, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication ↗

December 13, 2022

Via Benzinga

Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

December 13, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

December 01, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

November 29, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights

November 10, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

November 03, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting

October 26, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

October 06, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.